Market Overview

UPDATE: Wedbush Securities Initiates Regulus Therapeutics at Outperform on Pipeline Progress

Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015
Wedbush: Regulus Therapeutics Will Quadruple In Price Within 12 Months

Wedbush Securities initiated coverage on Regulus Therapeutics (NASDAQ: RGLS) with an Outperform rating and a $10 price target.

Wedbush Securities noted, "Regulus is developing oligonucleotide drugs that target microRNA, important regulators of gene expression whose dysregulation is implicated in a variety of diseases and disease states. Oligonucleotide drug discovery and development is rapid and predictable as drugs are assembled using the complementary microRNA target as a template, and other oligonucleotide drugs inform ADME, pK, safety and tolerability."

Regulus Therapeutics closed at $4.34 on Wednesday.

Latest Ratings for RGLS

Jun 2015Guggenheim SecuritiesInitiates Coverage onBuy
Apr 2015FBR CapitalInitiates Coverage onOutperform
Apr 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for RGLS
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (RGLS)

Get Benzinga's Newsletters